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January 29, 2013:479–84domized to receive a vitamin K antagonist but excludes the 2,283
participants who were randomized to receive idraparinux. Because
most of the bleeds in AMADEUS occurred in participants
randomized to receive idraparinux, the authors should also provide
c-statistics for major bleeding from these participants. For a valid
comparison, could they also provide c-statistics for major bleeding
from AMADEUS participants randomized to vitamin K antago-
nists, using each prediction score as a continuous variable but not
including INR variability? This variable is not available until after
the decision to initiate a vitamin K antagonist has already been
made.
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Reply
Dr. Singer and Drs. Gage and Radford dispute our use of
“clinically relevant bleeding” as a safety endpoint, but this was the
primary safety endpoint of the AMADEUS trial (1). Similarly, in
the recent ROCKET AF trial, the primary safety endpoint was the
composite of “major and clinically relevant non-major bleeding”
(2). Our published analysis already included data on major bleed-
ing while taking warfarin, but ultimately, clinically relevant bleed-
ing would be highly relevant to patients and clinicians who wish to
assess, in an informed manner (rather than by using guesswork),
those who are at risk of important bleeding events in everyday
clinical practice (3). Indeed, clinically relevant bleeding is indeed a
sensible and medically meaningful endpoint, both for patients and
physicians; in the AMADEUS trial, this robust endpoint was also
centrally and blindly adjudicated.
Dr. Singer and Drs. Gage and Radford request the data from
the idraparinux arm of the AMADEUS trial, and these have
recently been published as a separate analysis (4). We did not feel
that these data should be mixed with the warfarin data in our
primary paper (1), given the significant differences between the 2
arms in the number of bleeding events. Furthermore, the devel-
opment of idraparinux has ceased, and we made the pragmatic
decision that clinicians would be more interested in the perfor-
mance of these scores in warfarin-treated patients.
The analysis on intracranial bleeding is based on a small
number of events, as is always the case in assessment of rare
outcomes. Nevertheless, the retrieved area under the curve inreceiver-operator characteristic curve analysis provided accept-
able confidence intervals and a type I error probability of 3%.
The comments by Dr. Singer and Drs. Gage and Radford on
the clinical use of the HAS-BLED score are misinformed. The
“Labile INR” criterion (the L in HAS-BLED) only applies in a
patient already taking wafarin. If the HAS-BLED score is being
used to assess a nonanticoagulated patient’s potential bleeding
risk, then the labile INR criterion does not apply (and scores
zero). In its original validation paper, the c-indexes for HAS-
BLED in patients while taking vitamin K antagonists (VKA)
(0.72), as well as those on antiplatelet agents alone or no
antithrombotic therapy, were provided (c-indexes 0.91 and
0.85, respectively) (5). In addition, the labile INR criterion does
not apply with the non-VKA anticoagulants, but our validation
of the bleeding risk–prediction scores on idraparinux again
clearly shows the value of HAS-BLED in non-VKA
anticoagulation-treated patients (4).
However, risk assessment (whether for stroke or bleeding) is a
dynamic process and should be repeated at regular intervals after
the patient has begun antithrombotic therapy. This is when the
labile INR criterion should be applied (especially because INR
values should be available).
The HAS-BLED score has been shown to outperform the
more complex HEMORR2HAGES and less practical ATRIA
scores in other ‘real-world’ nontrial cohorts, even when major
bleeding was the comparative endpoint (6,7). The limitations of
he ATRIA score have also been highlighted previously (8).
Furthermore, a high HAS-BLED score (3) is predictive of
serious bleeding during bridging therapy, both in patients with
atrial fibrillation and those without (9).
How should HAS-BLED be used? A high HAS-BLED score
(3) is indicative of the need for regular review and follow-up but
should not be used as a reason for withholding or stopping oral
anticoagulation per se. The HAS-BLED score also makes clini-
cians think about the potentially correctable risk factors for
bleeding; for example, uncontrolled blood pressure (the H in
HAS-BLED), labile INRs if on warfarin (the L in HAS-BLED),
and concomitant use of aspirin/NSAIDs or excessive alcohol use
(the D in HAS-BLED). Finally, use of the HAS-BLED score has
been advocated in various international guidelines and consensus
documents [10–12].
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Straining With the Ventricular
Assist Device and Right
Ventricular Function
We read with great interest the paper by Grant et al. (1) in which
they provide an analysis to support the use of strain imaging as a
unique echocardiographic measure to predict right ventricular
(RV) failure in patients undergoing left ventricular assist device
(LVAD) placement. In their study, the value of RV strain was
assessed using a multivariate logistic regression analysis and was
found, not only to be significant in predicting RV failure, but also toprovide incremental value to the Michigan RV risk score (2). The
clinical relevance of such a prediction tool is not trivial because survival
is significantly reduced in LVAD patients with ensuing RV failure.
The challenge for the practitioner is that the current VAD
landscape is riddled with prognostic scores that hope to improve our
clinical decision making at the time of patient evaluation for device
candidacy. As the authors point out, no fewer than 8 strategies have
been published specifically assessing the RV (2–9). This is in addition
to at least 6 predictive risk scoring systems used to assess outcomes for
pulsatile and continuous flow LVADs (10–15).
Strain measurements with echocardiography are derived prin-
cipally from the deformation of the myocardial wall. Intuitively,
patterns of RV strain should reflect loading conditions. It would
have been revealing to determine the relationship between RV
strain and right atrial pressure in their study population. Further-
more, the true clinical question may not be whether the patient will
develop right ventricular failure, but instead, should a biventricular
assist device be implanted. Including data on those patients who
received a biventricular assist device would have provided even
more valuable insights into the application of RV strain assessment
in clinical practice.
The added value of RV strain to the many predictive indices for
RV failure post-LVAD is promising, and as the authors suggest,
will need to be further evaluated in a prospective multicenter
manner. In the end, it may be that the quest for a precise RV
prediction score is doomed to failure due to unanticipated events in
the operating room. Significant bleeding requiring multiple blood
transfusions, RV ischemia, and even accidental mechanical damage
to the RV can contradict a clinical prediction model and render a
patient with good RV function to one destined for RV failure after
LVAD implantation.
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